Kit for predicting pancreatic cancer patient prognosis adverse risks and application thereof
A technology for poor prognosis and pancreatic cancer, applied in the field of medicine and biology, can solve the problems of evaluating the prognosis of patients with less pancreatic cancer, lack of effective methods and products to evaluate the prognosis of pancreatic cancer patients, etc., and achieve the effect of easy promotion.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0022] Embodiment 1: Utilize the kit of the present invention to pancreatic cancer tissue (specimen is derived from the cancer tissue of surgical resection of 161 patients with pancreatic cancer, wherein 104 are male patients, 57 are female patients, the age span is 34-85 years old, the median 59 years old) expressed chemokine CXCL12 and chemokine receptor CXCR7 for detection
[0023] The pancreatic cancer prognosis kit in this embodiment consists of the following components:
[0024] (1) Reagent A: blocking solution, which is 10% goat serum;
[0025] (2) Reagent B: diluted ready-to-use anti-CXCL12 primary antibody;
[0026] (3) Reagent C: diluted ready-to-use anti-CXCR7 primary antibody;
[0027] (4) Reagent D: anti-goat biotinylated secondary antibody;
[0028] (5) Reagent E: streptavidin-labeled HRP;
[0029] (6) Reagent F: 20 times concentrated DAB substrate solution;
[0030] (7) Reagent G: 20 times concentrated DAB substrate buffer solution;
[0031] (8) Reagent H:...
Embodiment 2
[0067] Example 2 Application of the kit of the present invention in predicting the prognosis of pancreatic cancer patients
[0068] Using the case-control research method and using kits produced in small experiments, the expression of chemokine CXCL12 and chemokine receptor CXCR7 in the tissue samples of 161 patients with pancreatic cancer who underwent radical surgery were detected, and the expression of chemokine receptor CXCR7 was detected. Long-term follow-up of cancer patients (monthly telephone follow-up, follow-up for 87 months, no follow-up if the patient dies during the period), using statistical methods to study the chemokine CXCL12 and chemokine receptors in pancreatic cancer tissue The relationship between the intensity of CXCR7 expression and the prognosis of patients. like figure 2 As shown, the median survival time of CXCL12 and CXCR7 common high expression group was significantly shorter than CXCL12 and CXCR7 common low expression group and CXCL12 or CXCR7 hi...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com